Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy.

about

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy.

Item

http://www.wikidata.org/entity/Q43233004

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@en

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@nl

type

Item

label

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@en

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@nl

prefLabel

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@en

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@nl

P1476

Disease activity in axial spon ...... ion of TNF inhibitors therapy.

@en

P2093

Agata Sebastian

http://www.w3.org/2001/XMLSchema#string

Arkadiusz Chlebicki

http://www.w3.org/2001/XMLSchema#string

Małgorzata Mimier

http://www.w3.org/2001/XMLSchema#string

Patryk Wojtala

http://www.w3.org/2001/XMLSchema#string

Piotr Wiland

http://www.w3.org/2001/XMLSchema#string

Łukasz Lubiński

http://www.w3.org/2001/XMLSchema#string

P2860

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.

Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.

Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort.

Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.

ASAS classification criteria for axial spondyloarthritis: time to modify.

Remission and possible discontinuation of biological therapy in axial spondyloarthritis.

P304

157-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/REUM.2017.69775

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29056769

http://www.w3.org/2001/XMLSchema#string

P932

5647530

http://www.w3.org/2001/XMLSchema#string